PMID- 15992937
OWN - NLM
STAT- MEDLINE
DCOM- 20051107
LR  - 20061115
IS  - 0166-0934 (Print)
IS  - 0166-0934 (Linking)
VI  - 129
IP  - 2
DP  - 2005 Nov
TI  - Discriminating between serological responses to European-genotype live vaccine 
      and European-genotype field strains of porcine reproductive and respiratory 
      syndrome virus (PRRSV) by peptide ELISA.
PG  - 134-44
AB  - A peptide ELISA was developed based on an immunodominant and hypervariable 
      epitope in the ORF4 envelope glycoprotein of porcine reproductive and respiratory 
      syndrome virus (PRRSV). The peptide sequence was derived from the Porcilis 
      live-attenuated PRRSV vaccine strain (genotype 1, European). Antibodies induced 
      by the field PRRSVs currently circulating in Poland were not detected by the 
      Porcilis ORF4 peptide ELISA. In contrast, Porcilis-vaccinated animals 
      seroconverted in the ORF4 peptide ELISA at 21 days post-vaccination. Maximal 
      titers were seen 30-92 days post-vaccination; most sera had endpoint titers 
      between 1:1000 and 1:100,000. In a paired format, where sera were assayed in two 
      separate ELISAs using ORF4 peptides derived from the genetically very closely 
      related Porcilis and Lelystad PRRSV strains, it was possible to differentiate 
      between antibodies induced by these two viruses. The Porcilis and Lelystad ORF4 
      peptide ELISAs had sensitivities of 89 and 100%, respectively. Thus, ORF4 peptide 
      ELISA afforded specific detection of antibodies induced by an European-genotype 
      live-attenuated vaccine PRRSV strain (Porcilis). The results suggest that 
      specific ORF4 peptide ELISAs can be custom-made for European-genotype PRRSV 
      strains, using general peptide design criteria described in this work. Thus, ORF4 
      ELISAs may be generally useful, to monitor safety and operational aspects of 
      European-genotype live-attenuated PRRSV vaccine virus use in populations with 
      circulating field European-genotype PRRSVs.
FAU - Oleksiewicz, Martin B
AU  - Oleksiewicz MB
AD  - Novo Nordisk A/S, Virology and Molecular Toxicology, Novo Nordisk Park, Malov, 
      Denmark.
FAU - Stadejek, Tomasz
AU  - Stadejek T
FAU - Mackiewicz, Zbigniew
AU  - Mackiewicz Z
FAU - Porowski, Marian
AU  - Porowski M
FAU - Pejsak, Zygmunt
AU  - Pejsak Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Virol Methods
JT  - Journal of virological methods
JID - 8005839
RN  - 0 (Antibodies, Viral)
RN  - 0 (Epitopes)
RN  - 0 (Peptides)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antibodies, Viral/*blood
MH  - Enzyme-Linked Immunosorbent Assay/methods/*veterinary
MH  - Epitopes/genetics/immunology
MH  - Female
MH  - Genome, Viral
MH  - Injections, Intramuscular
MH  - Molecular Sequence Data
MH  - Open Reading Frames/genetics
MH  - Peptides/genetics/*immunology
MH  - Porcine Reproductive and Respiratory Syndrome/blood/*immunology
MH  - Porcine respiratory and reproductive syndrome virus/*immunology
MH  - Sensitivity and Specificity
MH  - Sequence Alignment
MH  - Species Specificity
MH  - Swine
MH  - Vaccination/*veterinary
MH  - Viral Envelope Proteins/genetics/*immunology
MH  - Viral Vaccines/administration & dosage/*immunology
EDAT- 2005/07/05 09:00
MHDA- 2005/11/08 09:00
CRDT- 2005/07/05 09:00
PHST- 2005/02/21 00:00 [received]
PHST- 2005/05/16 00:00 [revised]
PHST- 2005/05/17 00:00 [accepted]
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2005/11/08 09:00 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - S0166-0934(05)00170-9 [pii]
AID - 10.1016/j.jviromet.2005.05.017 [doi]
PST - ppublish
SO  - J Virol Methods. 2005 Nov;129(2):134-44. doi: 10.1016/j.jviromet.2005.05.017.